RPS21B Antibody

What is RPS21 and what are its primary cellular functions?

RPS21 (40S ribosomal protein S21) is a component of the small ribosomal subunit (40S) and plays a crucial role in protein synthesis. It functions primarily in the initiation of protein synthesis, participating in the early stages of translation . Beyond its canonical role in the ribosome, RPS21 has emerged as a potential oncogene with significant extra-ribosomal functions that affect cellular processes, particularly in cancer development and progression. Recent research has demonstrated that RPS21 can influence various cellular pathways, including those related to ferroptosis and oxidative stress response .

What experimental applications are RPS21 antibodies suitable for?

RPS21 antibodies have been validated for multiple experimental techniques, including:

• Western blotting (WB): Effective for detecting RPS21 protein expression levels in cell and tissue lysates

• Immunohistochemistry on paraffin-embedded sections (IHC-P): Useful for analyzing RPS21 localization and expression in tissue samples

• Immunocytochemistry/Immunofluorescence (ICC/IF): Allows for subcellular localization studies of RPS21 protein

The selection of a specific application should be guided by the research question and available validation data for the particular antibody being used .

What species reactivity is available for RPS21 antibodies?

Commercial RPS21 antibodies are typically validated for reactivity with human, rat, and mouse samples. When selecting an antibody, researchers should verify species cross-reactivity based on sequence homology and experimental validation. Polyclonal antibodies may offer broader species reactivity due to recognition of multiple epitopes, while monoclonal antibodies provide higher specificity but potentially more limited cross-reactivity .

How should researchers validate RPS21 antibodies before experimental use?

Proper validation of RPS21 antibodies should include:

• Positive and negative controls using tissues or cell lines with known RPS21 expression levels

• Verification of the expected molecular weight band (approximately 9 kDa) in Western blots

• Knockdown or knockout validation using siRNA or CRISPR-Cas9 systems to confirm specificity

• Comparison of staining patterns across multiple techniques (IHC, IF, WB) to ensure consistency

• Peptide competition assays to confirm epitope specificity

These validation steps are essential to minimize experimental artifacts and ensure reliable, reproducible results .

What approaches are most effective for quantifying RPS21 expression in tumor samples?

For accurate quantification of RPS21 expression in tumor samples, researchers should consider:

• Tiered approach combining techniques:

  • RT-qPCR for mRNA expression analysis

  • Western blotting with densitometry for protein quantification

  • IHC with digital image analysis for spatial expression patterns

• Tissue microarray (TMA) analysis:

  • Enables high-throughput analysis across numerous samples

  • Allows for standardized staining conditions across specimens

  • Facilitates correlation with clinical data

• Scoring system standardization:

  Score	Staining Intensity	Percentage of Positive Cells
  0	Negative	<5%
  1	Weak	5-25%
  2	Moderate	26-50%
  3	Strong	>50%

• Proper controls and normalization:

  • Include adjacent normal tissue for comparison

  • Use established housekeeping proteins as loading controls

  • Employ automated image analysis software to reduce observer bias

Research has demonstrated the prognostic value of RPS21 expression in hepatocellular carcinoma, with higher expression levels correlating with lower survival rates across multiple metrics (OS, PFS, RFS, DSS) .

How can RPS21's role in cancer progression be effectively investigated?

Based on current research methodologies, effective investigation of RPS21's role in cancer involves:

• In vitro functional assays:

  • Stable knockdown and overexpression models using lentiviral systems

  • Colony formation assays to assess proliferative capacity

  • EdU incorporation assays to measure DNA synthesis

  • Transwell and wound healing assays to evaluate migration potential

  • CCK-8 assays to measure cell viability

• In vivo models:

  • Subcutaneous xenograft models to assess primary tumor growth

  • Tail vein injection models to evaluate metastatic potential

  • Orthotopic models for tissue-specific cancer progression

• Molecular interaction studies:

  • Co-immunoprecipitation to identify protein binding partners

  • Ubiquitination assays to assess effects on protein stability

  • ChIP assays to determine transcriptional regulation

Recent studies have employed these approaches to establish RPS21's oncogenic role in hepatocellular carcinoma, demonstrating that RPS21 knockdown significantly reduces proliferation and migration capabilities while its overexpression enhances these processes .

What methodologies are appropriate for studying RPS21's influence on ferroptosis?

To investigate RPS21's role in ferroptosis regulation, researchers should consider:

• Ferroptosis induction and assessment:

  • Treatment with ferroptosis inducers (erastin, RSL3, sorafenib)

  • Measurement of lipid peroxidation (BODIPY-C11, MDA assay)

  • Assessment of glutathione levels (GSH/GSSG ratio)

  • Iron chelation rescue experiments

• GPX4 interaction studies:

  • Analysis of GPX4 expression levels following RPS21 modulation

  • Ubiquitination assays to assess RPS21's effect on GPX4 stability

  • Half-life determination using cycloheximide chase assays

  • Co-immunoprecipitation to detect direct or indirect interactions

• Redox status evaluation:

  • ROS measurement using fluorescent probes (DCFDA, DHE)

  • Assessment of antioxidant response elements

  • Analysis of ferroptosis-related gene expression patterns

Recent research has revealed that RPS21 can reduce the ubiquitination levels of GPX4, thereby stabilizing this key regulator of ferroptosis and ultimately enhancing cancer cell survival by inhibiting ferroptosis .

What are the optimal conditions for Western blot analysis of RPS21?

Given RPS21's relatively small size (9 kDa), Western blot analysis requires specific optimization:

• Sample preparation:

  • Use RIPA or NP-40 buffer with protease inhibitors

  • Sonicate samples briefly to ensure complete lysis

  • Centrifuge at high speed (14,000 × g) to remove insoluble material

• Gel electrophoresis:

  • Employ high percentage (15-20%) SDS-PAGE gels

  • Load appropriate positive controls (NIH-3T3, NBT-II cell lysates)

  • Use a molecular weight marker covering the low molecular weight range

• Transfer and detection:

  • Optimize transfer conditions for small proteins (higher methanol content)

  • Use PVDF membrane with 0.2 μm pore size rather than 0.45 μm

  • Block with 5% BSA in TBST rather than milk to reduce background

  • Use primary antibody at optimized concentration (e.g., 0.4 μg/mL)

  • Employ enhanced chemiluminescence with short exposure times

• Controls and validation:

  • Include lysates from cells with RPS21 knockdown as negative controls

  • Verify expected band size (9 kDa) with appropriate markers

  • Consider using loading controls appropriate for small proteins

These optimized conditions have been validated in studies using NIH-3T3 (mouse embryonic fibroblast) and NBT-II (rat bladder tumor) cell lysates .

What are the key considerations for immunohistochemical detection of RPS21?

For optimal immunohistochemical detection of RPS21 in tissue samples:

• Tissue processing:

  • Fixation in 10% neutral-buffered formalin for 24-48 hours

  • Proper dehydration and paraffin embedding

  • Section thickness of 4-5 μm for optimal antibody penetration

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Pressure cooker method (20 minutes) for consistent results

  • Allow sections to cool slowly to room temperature

• Antibody incubation:

  • Optimize antibody dilution (1:50 to 1:200 range)

  • Extended primary antibody incubation (overnight at 4°C)

  • Use appropriate detection system (polymer-HRP preferred)

• Evaluation and scoring:

  • Assess staining intensity and percentage of positive cells

  • Include both cytoplasmic and nuclear localization in evaluation

  • Compare with appropriate positive controls (fallopian tube, skin)

• Multiplexed analysis:

  • Consider dual immunostaining with markers like E-cadherin, N-cadherin, or Vimentin to assess correlation with epithelial-mesenchymal transition markers

Research has shown that RPS21 expression is significantly elevated in hepatocellular carcinoma tissues compared to adjacent normal tissues, with expression levels positively correlating with advancing tumor stage .

How should co-immunoprecipitation experiments involving RPS21 be designed?

When designing co-immunoprecipitation (Co-IP) experiments to investigate RPS21 interactions:

• Lysis conditions:

  • Use gentle lysis buffers (NP-40 or Triton X-100 based) to preserve protein complexes

  • Include protease inhibitors, phosphatase inhibitors, and RNase inhibitors

  • Maintain cold temperature throughout to prevent complex dissociation

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation

  • Consider using both N-terminal and C-terminal targeting antibodies

  • Use isotype-matched IgG controls

• Experimental approach:

  • Perform reciprocal Co-IPs (RPS21 → GPX4 and GPX4 → RPS21)

  • Include input controls (5-10% of lysate)

  • Consider crosslinking for transient or weak interactions

• Controls and validation:

  • Include RPS21 knockdown cells as negative controls

  • Verify specificity with competing peptides

  • Confirm results with alternative approaches (proximity ligation assay)

• Analysis considerations:

  • Assess both direct binding and involvement in larger complexes

  • Consider size-exclusion chromatography to isolate complexes

  • Employ mass spectrometry for unbiased identification of interactors

Recent research has utilized similar approaches to demonstrate that RPS21 influences the ubiquitination status of GPX4, suggesting protein-protein interactions that affect protein stability .

How can RPS21 expression be utilized as a prognostic biomarker in cancer research?

To effectively employ RPS21 as a prognostic biomarker in cancer research:

• Multi-cohort validation approach:

  • Establish expression thresholds through ROC curve analysis

  • Validate in independent patient cohorts

  • Correlate with established clinical parameters

• Integration with clinical data:

  • Use Kaplan-Meier survival analyses with various metrics (OS, PFS, RFS, DSS)

  • Perform univariate and multivariate regression analyses

  • Combine with other established biomarkers for improved prognostic value

• Technical standardization:

  • Establish standardized IHC protocols and scoring systems

  • Include quality control measures across different laboratories

  • Consider automated quantitative analysis for objectivity

Research using this approach has demonstrated that high RPS21 expression significantly correlates with poor patient outcomes across multiple survival metrics in hepatocellular carcinoma. Univariate and multivariate regression analyses of TCGA-LIHC data revealed that tumor T stage and RPS21 expression serve as independent prognostic indicators for HCC patient outcomes .

What approaches are most effective for targeting RPS21 in potential cancer therapies?

For researchers investigating RPS21 as a therapeutic target:

• Gene silencing strategies:

  • siRNA and shRNA approaches for transient and stable knockdown

  • CRISPR-Cas9 genome editing for complete knockout

  • Antisense oligonucleotides for clinical translation

• Small molecule development:

  • High-throughput screening for inhibitors of RPS21-GPX4 interaction

  • Structure-based drug design targeting RPS21 functional domains

  • Repurposing of existing drugs that may affect RPS21 function

• Combination therapy approaches:

  • Combining RPS21 targeting with ferroptosis inducers

  • Synergistic approaches with conventional chemotherapeutics

  • Integration with immunotherapy strategies

• Delivery optimization:

  • Nanoparticle-based delivery systems for siRNA/shRNA

  • Tumor-targeting strategies to improve specificity

  • Pharmacokinetic and biodistribution studies

Current research suggests that RPS21 shows promise as a novel therapeutic target for hepatocellular carcinoma based on its ability to enhance ferroptosis resistance in cancer cells, which could be exploited to increase tumor cell susceptibility to ferroptosis-inducing treatments .

How does RPS21 function in the context of tumor microenvironment and immune response?

This emerging research area involves investigating:

• Tumor-immune interactions:

  • Effects of RPS21 expression on immune cell infiltration

  • Correlation with immune checkpoint molecule expression

  • Impact on antigen presentation and processing

• Extracellular functions:

  • Potential role of RPS21 in extracellular vesicles

  • Paracrine signaling between tumor and stromal cells

  • Effects on tumor-associated macrophage polarization

• Methodological approaches:

  • Single-cell RNA sequencing of tumor microenvironment

  • Spatial transcriptomics for localization studies

  • 3D co-culture systems with immune components

While current research has not yet fully explored these aspects, the established role of RPS21 in cancer progression suggests potential implications for tumor-immune interactions that warrant further investigation .

What is the relationship between RPS21 and response to cancer therapies?

To investigate RPS21's role in therapy response:

• Drug sensitivity correlation:

  • High-throughput drug screening in cells with varied RPS21 expression

  • Patient-derived xenograft models for therapy response testing

  • Analysis of clinical samples pre- and post-treatment

• Resistance mechanism investigation:

  • Changes in RPS21 expression following treatment

  • Impact on cellular stress response pathways

  • Effects on apoptotic threshold and cell survival mechanisms

• Biomarker development:

  • Prediction of therapy response based on RPS21 expression

  • Monitoring of RPS21 levels during treatment

  • Combination with other predictive biomarkers

Recent findings suggesting RPS21's role in ferroptosis regulation indicate that it may influence response to therapies that induce oxidative stress or ferroptosis. The ability of RPS21 to stabilize GPX4 may contribute to therapy resistance by protecting cancer cells from oxidative damage and ferroptotic cell death .